Fractional exhaled nitric oxide for the management of asthma in adults: Systematic review

Article English OPEN
Essat, M. ; Harnan, S. ; Gomersall, T. ; Tappenden, P. ; Wong, R. ; Pavord, I. ; Lawson, R. ; Everard, M. (2016)
  • Publisher: European Respiratory Society

The aim of this review was to evaluate the clinical effectiveness of fractional exhaled nitric oxide (FeNO) measured in a clinical setting for the management of asthma in adults.\ud \ud 13 electronic databases were searched and studies were selected against predefined inclusion criteria. Quality assessment was conducted using QUADAS-2. Class effect meta-analyses were performed.\ud \ud Six studies were included. Despite high levels of heterogeneity in multiple study characteristics, exploratory class effect meta-analyses were conducted. Four studies reported a wider definition of exacerbation rates (major or severe exacerbation) with a pooled rate ratio of 0.80 (95% CI 0.63–1.02). Two studies reported rates of severe exacerbations (requiring oral corticosteroid use) with a pooled rate ratio of 0.89 (95% CI 0.43–1.72). Inhaled corticosteroid use was reported by four studies, with a pooled standardised mean difference of −0.24 (95% CI −0.56–0.07). No statistically significant differences for health-related quality of life or asthma control were found.\ud \ud FeNO guided management showed no statistically significant benefit in terms of severe exacerbations or ICS use, but showed a statistically significant reduction in exacerbations of any severity. However, further research is warranted to clearly define which management protocols (including cut-off points) offer best efficacy and which patient groups would benefit the most.
  • References (8)

    1 Royal College of Physicians. Why Asthma Still Kills: the National Review of Asthma Deaths (NRAD). www. asthma.org.uk/globalassets/campaigns/nrad-full-report.pdf Date last accessed: June 1, 2015. Date last updated: May, 2014.

    2 British Thoracic Society (BTS). The Burden of Lung Disease. 2nd Edn. A statistics report from the British Thoracic Society. www.brit-thoracic.org.uk/document-library/delivery-of-respiratory-care/burden-of-lung-disease/ burden-of-lung-disease-2006/ Date last accessed: accessed 1 June 2015. Date last updated: 2006.

    3 Dahl R. Systemic side effects of inhaled corticosteroids in patients with asthma. Respir Med 2006; 100: 1307-1317.

    4 British Thoracic Society (BTS), Scottish Intercollegiate Guidelines Network (SIGN). British Guideline on the Management of Asthma: a National Clinical Guideline. Revised 2014. www.brit-thoracic.org.uk/guidelines-and-quality-standards/asthma-guideline/ Date last accessed: June 2, 2015. Date last updated: October 8, 2014.

    5 Dweik RA, Boggs PB, Erzurum SC, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med 2011; 184: 602-615.

    6 Schleich FN, Seidel L, Sele J, et al. Exhaled nitric oxide thresholds associated with a sputum eosinophil count ⩾3% in a cohort of unselected patients with asthma. Thorax 2010; 65: 1039-1044.

    7 Pavord ID, Shaw DE, Gibson PG, et al. Inflammometry to assess airway diseases. Lancet 2008; 372: 1017-1019.

    8 Berry M, Morgan A, Shaw DE, et al. Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma. Thorax 2007; 62: 1043-1049.

  • Related Research Results (1)
  • Similar Research Results (1)
  • Bioentities (1)
    1iii Protein Data Bank
  • Metrics
    0
    views in OpenAIRE
    0
    views in local repository
    18
    downloads in local repository

    The information is available from the following content providers:

    From Number Of Views Number Of Downloads
    White Rose Research Online - IRUS-UK 0 18
Share - Bookmark